Experimental drug shows promise for rare immune disorders
NCT ID NCT01842386
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times
Summary
This early-phase study tested rituximab, a drug used for rheumatoid arthritis, in 7 adults with rare diseases where the immune system attacks the body's own proteins. The goal was to see if the drug is safe and can help control these hard-to-treat conditions. Participants received several doses over 6 months and were followed for 18 more months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ALVEOLAR PROTEINOSIS (PAP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.